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Abstract
Background: The vitamin D receptor (VDR) pathway is important in the prevention and potentially in the treatment of many
cancers. One important mechanism of VDR action is related to its interaction with the Wnt/b-catenin pathway. Agonist-
bound VDR inhibits the oncogenic Wnt/b-catenin/TCF pathway by interacting directly with b-catenin and in some cells by
increasing cadherin expression which, in turn, recruits b-catenin to the membrane. Here we identify TCF-4, a transcriptional
regulator and b-catenin binding partner as an indirect target of the VDR pathway.
Methodology/Principal Findings: In this work, we show that TCF-4 (gene name TCF7L2) is decreased in the mammary
gland of the VDR knockout mouse as compared to the wild-type mouse. Furthermore, we show 1,25(OH)2D3 increases TCF-4
at the RNA and protein levels in several human colorectal cancer cell lines, the effect of which is completely dependent on
the VDR. In silico analysis of the human and mouse TCF7L2 promoters identified several putative VDR binding elements.
Although TCF7L2 promoter reporters responded to exogenous VDR, and 1,25(OH)2D3, mutation analysis and chromatin
immunoprecipitation assays, showed that the increase in TCF7L2 did not require recruitment of the VDR to the identified
elements and indicates that the regulation by VDR is indirect. This is further confirmed by the requirement of de novo
protein synthesis for this up-regulation.
Conclusions/Significance: Although it is generally assumed that binding of b-catenin to members of the TCF/LEF family is
cancer-promoting, recent studies have indicated that TCF-4 functions instead as a transcriptional repressor that restricts
breast and colorectal cancer cell growth. Consequently, we conclude that the 1,25(OH)2D3/VDR-mediated increase in TCF-4
may have a protective role in colon cancer as well as diabetes and Crohn’s disease.
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Introduction
Activation of the vitamin D pathway has been associated with a
decreased risk in the development and progression of many
cancers (reviewed in[1]). Although epidemiologic studies are less
clear regarding the association of cancer risk with serum levels of
vitamin D and its metabolites, molecular biology and animal
studies support a role for vitamin D in increased apoptosis and cell
differentiation, and decreased cell growth. As vitamin D is a
compound that is available in the diet (albeit insufficiently) as a
supplement, or readily-synthesized by the body, it is an attractive
candidate for chemoprevention and chemotherapy. Its clinical
benefit in this capacity, however, is inhibited by dose-limiting
hypercalcemia, a side-effect that develops from the primary role of
vitamin D in calcium homeostasis. In an effort to utilize vitamin D
in the clinic as an anti-cancer agent, efforts have been made to
generate vitamin D analogs which result in reduced hypercalce-
mia. While these analogs have shown great promise in vitro and in
animal models, they fall short in evoking an equivalent response in
the clinic. Furthermore, a successful analog may pose a particular
problem in the context of colorectal cancer, the third leading cause
of cancer-related death in men and women in the US. Although
the evidence for vitamin D as an anti-cancer agent in this organ is
particularly strong, the GI tract is intimately involved in mediating
the effects of vitamin D on calcium homeostasis. This indicates
that in the colon, it may be difficult to uncouple the anti-cancer
and calcium homeostatic effects of vitamin D. Although, in other
studies we show that some vitamin D partial antagonists will
activate the vitamin D receptor in cells which express high levels of
activated b-catenin (cancer cells) but not in normal cells and may
have the potential to do this [2].
Nuclear hormone receptors can influence the canonical Wnt
signaling cascade by interacting with b-catenin [3]. This
phenomenon may be particularly relevant in colon cancer, where
80% of cases are a harbor of APC mutations that aberrantly
activate b-catenin [4], leading to accumulation of activated b-
catenin in the nucleus (Reviewed in [5]). Within the nucleus, b-
catenin is responsible for co-activating the transcription of genes
whose promoters are occupied by members of the TCF/LEF
family of transcription factors. Some of these genes such as c-myc
[6] and Cyclin-D1 [7], are involved in cell cycle regulation and can
contribute to an oncogenic phenotype. Treatment of cells with
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7872some (but not all) nuclear hormone receptor (NHR) agonists
causes an up-regulation of NHR-responsive genes while simulta-
neously causing a decrease in TCF/b-catenin target gene
transcription. This has been attributed to competitive binding
between TCF and NHRs for b-catenin [3,8–11], and/or common
co-activators such as p300 [2]. A second mode of inhibition of Wnt
target gene transcription has been attributed to the prevention of
b-catenin nuclear translocation by recruitment of cytoplasmic b-
catenin to adherens junctions [9,12,13]. Thirdly, there is evidence
that NHRs bind to TCF/LEF family members, directly, and
thereby inhibit transcription of TCF/b-catenin responsive genes
[14–18]. This is probably due to recruitment of co-repressors such
as TLE (Groucho) [19], NCoR and SMRT [20].
Here we report an additional mechanism of interaction between
the b-catenin pathway and the vitamin D receptor (VDR)
pathway. To clarify, we will use the following nomenclature:
TCF7L2 in the context of plasmids, DNA and RNA, and TCF-4
in the context of protein, only. We found that TCF-4 is
differentially expressed in cells derived from DMBA-induced
mouse mammary tumors from VDR wild-type and knock out
mice, and the mammary glands themselves. Further exploration
revealed a VDR-dependent up-regulation of TCF7L2 at the
mRNA and protein levels by treatment with 1,25(OH)2D3 in
CaCo2 cells. Analysis of the human and mouse TCF7L2 promoter
predicted several putative vitamin D receptor binding elements
proximal to the transcription start site. Although cloning of this
promoter region revealed regulation by the VDR/1,25(OH)2D3,
subsequent mutation analysis, chromatin immunoprecipitation
and protein synthesis-inhibition experiments indicate that this
effect is likely conveyed indirectly, via a VDR/1,25(OH)2D3-
sensitive intermediary. Increases in TCF-4 protein levels translate
to increased TopFlash activity after 24 hours of ligand treatment
in CaCo2 cells. We propose a mechanism whereby this effect may
inhibit oncogenic activity in cellulo.
Results
Mammary Glands from VDR Knockout Mice Have Less
TCF-4 than Mammary Glands from VDR Wild-Type Mice
VDR145
+/+ and VDRK240
2/2 cell lines are derived from
DMBA-induced mouse mammary tumors from wild-type (WT)
and VDR knockout (KO) mice, respectively and were described
previously [21]. VDR KO mice are more susceptible to
carcinogen-induced mammary and colon carcinogens as well as
other lesions [22,23]. Preliminary experiments indicated that
TCF-4 was more abundant in WT cells than KO cells (not shown).
We performed western blot analysis for TCF-4 and confirmed that
VDRK240
2/2 cells have very low levels of TCF-4 compared to
VDR145
+/+ cells (Figure 1A). We next performed a pull-down
assay in which we used two GST-tagged b-catenin fusion proteins.
WT GST-tagged b-catenin binds TCF/LEFs via the armadillo
repeat region, whereas GST-dTCF-b-Cat, which harbors muta-
tions at residues 253, 312, and 435 within the armadillo region,
has dramatically-reduced affinity for TCF/LEFs [24]. Consistent
with the western blot data, the WT fusion protein pulled down
more TCF-4 from VDR145
+/+ lysates than from VDRK240
2/2
lysates. The mutated fusion protein pulled-down much less TCF-4
from the VDR145
+/+ cells and none from the VDRK240
2/2 cells
(Figure 1B).
We next used the OT/OF reporter system to assay TCF/b-
catenin activity in these cells. The OT reporter contains three
tandem TCF/LEF binding elements upstream of a luciferase gene
and the corresponding control reporter (OF) has mutated TCF
binding sites and represents background binding. Because these
cells have low endogenous b-catenin activity, VP16-b-catenin was
co-expressed with the reporter vectors in all samples. Consistent
with their reduced levels of TCF-4, VDRK240
2/2 cells had less
b-catenin activity than VDR145
+/+ cells (Figure 1C). This
difference was significant but not large and indicates that
VDRK240
2/2 cells have other TCF family members that can
compensate for TCF-4, and/or the low levels of TCF-4 that
remain in these cells is sufficient for activation, at least in the
context of high levels of activated b-catenin [25,26]. Co-
transfection with exogenous TCF7L2 rescued the reduced b-
catenin activity in the VDRK240
2/2 cells (Figure 1D). To
determine whether this phenomenon was also happening in vivo,
we stained normal mammary tissues from VDR WT and VDR
KO mice for TCF-4. In concordance with the rest of the data in
Figure 1, mammary tissues from VDR WT animals have more
prominent staining compared to mammary tissues from VDR KO
animals (Figure 1E). TCF-4 staining is not completely absent in
VDR KO mammary glands, although it is much less frequent and
less intense (Figure 1E, bottom right panel).
CYP24A1 is the best-characterized, downstream target of the
vitamin D pathway and its mRNA is exquisitely sensitive to VDR
agonists. CYP24A1 is involved in the metabolism of active vitamin
D compounds into inactive metabolites. Activity of the CYP24A1
reporter was absent and not affected by 1,25(OH)2D3 in
VDRK240
2/2 cells but was restored upon transfection of VDR
(Figure 2A). Collectively, these data show that cells that are null for
the VDR have lower basal levels of TCF-4 and that this diminishes
b-catenin activity in our VDR-null mammary model.
VDR/1,25(OH)2D3 Regulates TCF7L2 mRNA and Protein in
Colorectal Cancer Cell Lines
We next transfected VDRK240
2/2 cells with human VDR and
found that TCF-4 protein and TCF7L2 mRNA were unaffected
by VDR or 1,25(OH)2D3 (Supplementary Figure S1A and S1B).
Remarkably, even though the activity of the CYP24A1 reporter
was sensitive to exogenous VDR and 1,25(OH)2D3 in these cells
(Figure 2A), like TCF7L2, endogenous CYP24A1 mRNA was not,
despite transfection optimization that allowed us to achieve 60%
efficiency (Figure 2B). These data indicate that VDRK240
2/2
cells have long-lived alterations in the ability of endogenous target
genes to respond to the transient restoration of VDR. As
exogenously expressed promoters are sensitive, this is likely a
result of changes in chromatin organization which cannot be
reversed by short term expression of VDR and treatment with
1,25(OH)2D3.
Consequently, to further determine the effects of VDR and its
classical ligand on TCF-4 expression, we assayed several colorectal
cancer cell lines for changes in TCF-4 expression in response to
1,25(OH)2D3 (Figure 2C, Supplementary Figure S2). Although all
of these cells increased expression of TCF4 in response to vitamin
D we chose to use the human colorectal adenocarcinoma cell line,
CaCo2 for several reasons. These cells are well-studied in the
context of vitamin D signaling and their growth is inhibited by
1,25(OH)2D3 [27]. Furthermore, they are a unique system that
mimics normal gut epithelium as once they become confluent they
differentiate in culture [28]. These cells also express VDR, but at
lower (i.e. normal) levels with respect to several other colon cancer
cell lines [29,30]. Treatment of confluent CaCo2 cells with
10
27 M 1,25(OH)2D3 with or without transfection of VDR lead to
a robust and statistically significant increase in TCF-4 protein
(Figure 2D and E). The effects of 1,25(OH)2D3 are modestly
potentiated by exogenous VDR and this is likely an underestimate
as only 50–60% of the cells are transfected. More importantly, the
increase in TCF-4 induced by 1,25(OH)2D3 is absolutely
Vitamin D Regulates TCF-4
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+/+ cells have more basal TCF-4 than VDRK240
2/2 cells. (A) Western blot of whole cell lysates, in duplicate, from VDR145
+/+
(VDR +/+) cells (lanes 1 and 2) and VDRK240
2/2 (VDR 2/2) cells (lanes 3 and 4) probed for TCF-4, VDR and GAPDH. (B) Pull-down of proteins in VDR
+/+ and VDR 2/2 lysates with GST-tagged b-catenin constructs and probed for TCF-4. GST-WT-b-catenin (GST-b-Cat) is used in lanes 1 and 2.
Mutated b-catenin that will not effectively bind TCF/LEF proteins (GST-dTCF-b-Cat) is used in lanes 3 and 4. Beads alone are used in lanes 5 and 6. (C)
OT activity in VDR +/+ and VDR 2/2 cells transfected with Renilla and VP16-b-catenin. Data are normalized to Renilla. Error bars represent SEM. p-
values represent student’s t-test for significan differences between cell lines. RLU: Relative Light Units (D) OT activity in VDR +/+ and VDR 2/2 cells
transfected with Renilla, VP16-b-catenin and with or without a TCF7L2 plasmid. Error bars represent SEM. Statistics are student’s t-test for differences
between transfected and control-transfected cells. *p,.05; ***p,.0005. (E) Mammary gland tissues from VDR WT (top panels) and VDR KO (bottom
panels) mice stained for TCF-4 shown at three magnifications.
doi:10.1371/journal.pone.0007872.g001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7872Figure 2. TCF-4 is increased by 1,25(OH)2D3 in a VDR-dependent manner in human colorectal cancer cells. (A) CYP24-luc activity in
VDRK240
2/2 (VDR 2/2) and VDR145
+/+ (VDR +/+) cells that were transfected with GFP or VDR and treated with 10
27 M 1,25(OH)2D3 or EtOH-control
for 24 hours as indicated. RLU=Relative Light Units. (B) Reverse Transcriptase PCR analysis of mouse CYP24A1 (top panel), mouse and human VDR
(middle panels) and b-actin (bottom panel) transcripts in response to exogenous human VDR expression and 1,25(OH)2D3 treatment as described in
part A. (C) Various colorectal cancer cell lines were incubated for 24 hours in 10
27 M 1,25(OH)2D3 or EtOH, as indicated. Cellular proteins were
assayed for TCF-4 expression (upper panel) and GAPDH was monitored for equal lane loading (lower panel). Both TCF-4 bands represent different
isoforms of TCF-4 that have different length C-termini. (D) CaCo2 cells were transfected with different amounts of VDR or siRNA for 24 hours and
treated with 10
27 M 1,25(OH)2D3 or EtOH for a subsequent 24 hours, as indicated, and probed for TCF-4. NT: Non-targeting. (E) Densitometric
analysis of three western blots as indicated in part A. Data were plotted relative to each EtOH-treated control. p-values were generated by one-tailed
t-test: * p,.05; ** p,.005; *** p,.0005 (F) CaCo2 cells were transfected for 24 hours with VDRE-luc, Renilla and siRNA and treated for a subsequent
24 hours with 10
27 M 1,25(OH)2D3 as indicated. RLU: Relative Light Units. (G) CaCo2 cells were transfected with siRNA for 24 hours and treated for a
subsequent 24 hours with 10
27 M 1,25(OH)2D3 or EtOH as indicated. CYP24A1 transcripts were assayed by qPCR. Data are normalized to GAPDH
expression and plotted relative to each EtOH control.
doi:10.1371/journal.pone.0007872.g002
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effects of 1,25(OH)2D3 on the activity of a VDRE promoter
reporter and on CYP24A1 mRNA induction, but also on TCF-4-
induction (Figure 2D–G). In contrast to VDRK240
2/2 cells
(Supplementary Figure S1B), TCF7L2 and CYP24A1 mRNAs
were increased by 1,25(OH)2D3 in CaCo2 cells (Figure 3A). Both
TCF7L2 and CYP24A1 levels were elevated after 4 hours with
TCF7L2 reaching a maximum induction at 24 hours (Figure 3B).
This regulation is also subject to cell density, as statistically
significant differences in TCF7L2 mRNA are only seen at higher
density (Supplementary Figure S3). This may be analogous to the
modestly potentiated effects of exogenous VDR on 1,25(OH)2D3-
mediated increase of TCF-4 (Figure 2E), as CaCo2 cells are known
to up-regulate VDR upon confluence/differentiation [31].
VDR/1,25(OH)2D3 Regulates the Activity of the TCF7L2
Promoter in Mouse Mammary and Human Colorectal
Cancer Cells
Since TCF7L2 is regulated by 1,25(OH)2D3 at the mRNA level in
CaCo2 cells, we scanned the mouse and human TCF7L2 genes
approximately 4000 base-pairs upstream of the transcription start site
for the presence of half-sites that conform to the VDRE consensus
RGKTSA(R=AorG,K=GorT;S=GorC),orhalf-sitesthat
deviate slightly from the consensus but that have been described as
functional VDRE half-sites in the literature. We identified several
putative VDREs encoded on the TCF7L2 promoter of both the
human and mouse gene (Supplemental Table S1 [32–41]). Since the
mouse and the human TCF7L2 promoter share more than 80%
sequence identity in the first ,2000 base pairs, we cloned two
portionsofthemousepromoterintoaluciferaseconstruct(Figure4A).
One reporter, -1037-luc, contains the region between +522 and
2515 basepairs relative to the transcription start site and contains the
5’UTR and the predicted TATA box at 225 basepairs. The -2068-
luc reporter spans the region between +430 and 21 5 4 2re la t iv et ot h e
transcriptional start site. The plasmid names and subsequently-
mentioned VDREs refer to the distance from the start codon and not
the transcription start site since database transcription start sites vary.
The half-sites of the 2187/2177 DR4 elements, (two hexameric
half-sites arranged as direct repeats spaced by four nucleotides) share
one half-site between them.
Reporter -1037-luc contains the first putative, compound VDRE
only, while the -2068-luc reporter contains all four VDREs. p53
Figure 3. Characterization of TCF7L2 up-regulation in response to 1,25(OH)2D3. (A) qPCR analysis of CaCo2 cells transfected and treated as
described in Figure 2D and 2E. TCF7L2 (left panel) and CYP24A1 (right panel) transcripts. Data are normalized to GAPDH and plotted relative to each
EtOH-treated control. p-values are derived from student’s t-test comparison between EtOH and D3 controls: * p,.05; **; p,.005; *** p,.0005 (B)
CaCo2 cells were treated at different time points with 10
27 M 1,25(OH)2D3 up to 48 hours before collection. mRNA for TCF7L2 (left panel) and
CYP24A1 (right panel) was assayed by qPCR. Data were normalized to GAPDH and plotted as fold change relative to the 0 Hr timepoint. p-values
were derived from student’s t-test as compared to 0 Hr timepoint: * p,.05; **; p,.005; *** p,.0005.
doi:10.1371/journal.pone.0007872.g003
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that p53 also inhibited the activity of both -2068-luc and -1037-luc
mouse reporters [42,43] (Figure 4B). Furthermore, basal activity of
the -2068-luc reporter was markedly less than the -1037-luc reporter
indicating the presence of a strong repressor element in this region
(Figure 4B). In CaCo2 cells, the -1038-luc construct responds
modestly, but significantly, to the addition of ligand but the effect was
not potentiated by exogenous VDR (Figure 4C, left panel). In
contrast, -2068-luc responds strongly to exogenous VDR but not to
treatment with 1,25(OH)2D3 in CaCo2 and VDRK240
2/2 cells
(Figure 4C, right panel and Supplementary Figure S4A, respectively).
These data indicate that VDR and treatment with 1,25(OH)2D3
influences the activity of the TCF7L2 promoter but they do not
demonstrate that the effect is direct.
Putative VDREs within the Mouse TCF7L2 Promoter Are
Not Important for Regulation by VDR in Mouse Mammary
and Human Colorectal Cancer Cells
To test the hypothesis that the putative VDREs were important
in conveying the response of the TCF7L2 promoter to the VDR,
the third and fourth nucleotides within each half-site were mutated
Figure 4. Mouse TCF7L2 promoter reporter constructs respond to VDR or 1,25(OH)2D3. (A) Two mouse TCF7L2 promoter constructs were
clonedupstreamofaluciferasereporter.ThefourputativeVDRElocationsrelativetothetranslationstartsitearedenoted,andallVDREsareencoded on the
non-coding strand. The 2177 and 2187 VDREs are overlapping and share a half-site between them. The 21037 construct (-1037-luc) contains the region
from 21t o21037 relative to the translation start site and possesses the 2177/2187 VDRE, only, while the 22068 reporter (-2068-luc) contains the region
between 296 and 22068 relative to the translation start site of the mouse TCF7L2 promoter, and possesses all four putative VDREs. (B) CaCo2 cells were
transfected for 24 hours with Renilla and reporters as indicated as well as different amounts of p53. Data are normalized to Renilla and to empty reporter
expression.RLU=RelativeLightUnits.(C)-1038-LucoremptyvectorconstructsweretransfectedintoCaCo2cellswithRenillaanddifferent amountsofVDR,
as indicated.24 hoursaftertransfection,cells weretreatedforanadditional24 hourswith10
27 M1,25(OH)2D3 or EtOH vehicle control. Error bars represent
SEM. Statistics were derived from two-way ANOVA for differences between EtOH- and 1,25(OH)2D3-treated samples: * p,.05; **; p,.005; *** p,.0005. (D)
CaCo2 cells were transfected, treated and analyzed as in part C using -2068-luc instead of -1038-luc. Statistics were generated by two-way ANOVA for
significant differences between the amount of VDR transfected: *** p,.0005. Error bars represent SEM. RLU: Relative Light Units.
doi:10.1371/journal.pone.0007872.g004
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not mutated since the 39half-site if this VDRE is shared with 2178
VDRE, and was mutated in that construct. These mutations alter
the half-sites such that they do not conform to the VDRE
consensus sequence, and should not bind VDR. Mutations were
generated such that each VDRE (containing two half-sites, each)
Figure 5. Putative VDREs within the TCF7L2 Promoter are not Responsible for 1,25(OH)2D3-VDR-mediated increase of TCF7L2. (A)
Graphical representation of the four putative VDREs within the first ,1500 base-pairs of the mouse TCF7L2 promoter and their sequences. DR3: direct
repeat interspersed by three nucleotides. 2xDR4: two, overlapping direct repeats interspersed by four nucleotides. Although the putative VDREs are
encoded on the non-coding strand, their sequences are written in reverse-complement such that the VDREs can be identified as conforming to the
RGKTSA consensus. (B) -2068-luc construct containing all three sets of half-site mutations (d1502/d1153/d177) was transfected into CaCo2 cells and
treated with ligand as described in Figure 4C with only 3 concentrations of VDR (low, medium and high). Error bars represent SEM. Statistics represent
analysis using two-way ANOVA: *p,.05. RLU-Relative Light Units. (C) Depiction of the six putative VDREs identified within 4000 base-pairs upstream
of the transcription start site of the human TCF7L2 promoter region and are named relative to their distance from the translation start site (+ being
downstream, and–being upstream). All regions except +88 (marked with ˆ) are encoded on the non-coding strand. (D) Chromatin
immunoprecipitation of VDR and RXR-bound DNA fragments from CaCo2 cells treated for 4 hours with 10
27 M 1,25(OH)2D3 (D-even-numbered
lanes) or EtOH (E-odd-numbered lanes). The regions that amplify VDRE-containing regions are denoted along the top of the lanes. The CYP product
amplifies a region of the human CYP24A1 promoter that is known to bind VDR and RXR in the presence of ligand and serves as a positive control. IgG
represents non-specific amplification. Input demonstrates equivalent material used in each sample.
doi:10.1371/journal.pone.0007872.g005
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double mutations, and one triple mutation. Transfection of these
constructs revealed that they retained responsiveness to exogenous
VDR in CaCo2 cells and VDRK240
2/2 (Figure 5B and
Supplementary Figure S4B, respectively). We next performed
chromatin immunoprecipitation (ChIP) assays to test the recruit-
ment of the VDR to the six putative VDREs identified within the
human TCF7L2 promoter (Figure 5C). CaCo2 cells were seeded
at high density and treated for 4 hours with 10
27 M 1,25(OH)2D3.
Both the Retinoid X Receptor (RXR) and the VDR were
recruited to the published VDREs on the CYP24A1 promoter
(Figure 5D, lanes 1 and 2), however, neither NHR was recruited to
any of the putative VDREs in the human TCF7L2 promoter
region. These data suggest that the increase in TCF7L2 expression
is not due to recruitment of the VDR to these putative VDREs in
the mouse and human TCF7L2 promoters. This could mean that
either the VDR is being recruited to other regions of the genome
and controlling the transcription of TCF7L2 directly, or the VDR
is regulating this phenomenon through a 1,25(OH)2D3-sensitive
intermediary.
Regulation of TCF7L2 by VDR/1,25(OH)2D3 Is Likely
Mediated by an Indirect Mechanism in Colorectal Cancer
Cells
To test the latter hypothesis, we employed the translation
inhibitor, cycloheximide (CHX). CaCo2 cells were pre-treated
with different amounts of CHX for 30 minutes and then treated
with 10
27 M 1,25(OH)2D3 for 24 hours. In CaCo2 cells, at
concentrations as low as 12.5 mg/mL, CHX was able to
significantly block induction of TCF7L2 mRNA by1,25(OH)2D3,
as is DKK-4, another indirect vitamin D target that is negatively-
regulated (Figure 6) [44]. These data indicate the requirement for
de novo protein synthesis for regulation by 1,25(OH)2D3. The
CYP24A1 mRNA induction by 1,25(OH)2D3 is also markedly
inhibited by CHX, but is still induced ,20 fold by 1,25(OH)2D3 at
the highest concentration of CHX (Supplementary Figure S5), a
phenomenon that has been shown for another direct vitamin D
target gene, E-cadherin [9]. The regulation of CYP24A1 is so
dramatic that it probably requires the continued synthesis of co-
activator proteins to support an induction of this magnitude.
Taken together, these data imply that the regulation of TCF7L2
by VDR/1,25(OH)2D3 is indirect.
1,25(OH)2D3 Increases TCF Reporter Activity in Colorectal
Cancer Cells
While the regulation of TCF7L2 is important for many
pathologic outcomes, we wanted to look at it in the context of
cancer. We chose to look at the effects of VDR-mediated TCF-4
up-regulation via the classical TopFlash reporter system that has
been previously described (TopFlash, unlike OT, utilizes a
minimum c-fos promoter). CaCo2 cells have a somatic APC
mutation that allows b-catenin to accumulate and translocate to
the nucleus. In the case of over-abundant, active b-catenin we can
expect an increase in TCF7L2 expression to result in increased
TopFlash activity. Indeed, we repeated the same VDR titration
experiments as described in the TCF7L2 promoter reporter
experiments (Figure 4C), using TopFlash (normalized to the
control plasmid, FopFlash) instead, and observed a consistent,
significant increase in TopFlash activity with 24 hours of 10
27 M
1,25(OH)2D3 in CaCo2 cells (Figure 7) that, like the protein data
(Figure 2D and 2E) is potentiated by the VDR. These data support
a role for VDR-dependent, 1,25(OH)2D3-mediated increase of
TCF-4 in mouse mammary and human colorectal tumor cells, the
effects of which may differentially regulate b-catenin activity in
vivo.
Discussion
Vitamin D has shown great promise as an anti-cancer agent in
both molecular and animal studies, as well as some epidemiolog-
ical studies (Reviewed in [45]). In an effort to uncouple the anti-
cancer effects of vitamin D from the calcemic effects that limit its
usefulness in the clinic, many labs are dissecting its downstream
activities. Several molecular mechanisms that contribute to the
Figure 6. Cycloheximide treatment abolishes 1,25(OH)2D3-
induced TCF7L2 mRNA induction. CaCo2 cells were pre-treated
for 30 minutes with different concentrations of the protein synthesis
inhibitor Cycloheximide (CHX) before addition of 10
27 M 1,25(OH)2D3
or EtOH for 24 hours, as indicated. Analysis of mRNA abundance of
TCF7L2 (top panel) and DKK4 (bottom panel) was assayed by qPCR.
Error bars represent SEM. * p,.05 via student’s t-test for significant
differences between D3 versus EtOH treated cells.
doi:10.1371/journal.pone.0007872.g006
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the b-catenin pathway. A direct interaction between b-catenin and
a NHR, in this case, retinoic acid receptor was first described in
1999 [3]. Since then, many studies have found similar interactions
for androgen receptor [8,10,11], peroxisome proliferator activated
receptor [18], and VDR [2,9]. These studies show that the NHR
and TCF/LEF family members compete for binding to b-catenin
and/or common co-activators, such as p300. In the presence of
ligand, b-catenin and/or p300 favors binding to the NHR, causing
a synergistic up-regulation (in conjunction with NHR ligand) of
NHR-regulated genes, as well as a simultaneous down-regulation
of TCF/b-catenin responsive genes. Cadherins have also been
described as downstream targets of NHR pathways [9,12,13].
Cadherins can prevent nuclear localization of b-catenin by
recruiting it from the cytoplasm to adherens junctions in the
membrane, causing a putative, latent inhibition of TCF/b-catenin
activity as well as a return to ‘basal’ levels of ligand-activation of
NHR-responsive genes. Yet a third mechanism involves the
binding of NHRs to TCF/LEF family members [14–18]. Many of
these assays support TCF/LEF family members in their role as
transcriptional repressors, likely by recruitment of other co-
repressors such as TLE [19], and NCoR and SMRT [20].
Furthermore, it has been shown that once TCF/LEFs are bound
by co-represssors, they are not easily displaced by activated b-
catenin [17,20].
The present study describes another mode of crosstalk between
the VDR and b-catenin pathways by demonstrating that
TCF7L2/TCF-4, itself, is regulated by VDR/1,25(OH)2D3 in
human colorectal cancer cell lines and likely in the mammary
gland as well. This induction is unique to TCF-4, as other TCF/
LEF family members are not up-regulated (Supplementary Figure
S6). Interestingly, LEF-1 is decreased upon treatment with ligand,
an effect that may demonstrate opposing functions for LEF-1 and
TCF-4 in the colon. A similar phenomenon occurs in the
differentiation of keratinocytes [46]. In this case one TCF family
member (TCF-3) inhibits keratinocyte differentiation and another
(LEF-1) stimulates it.
Surprisingly, considering the central role of TCF7L2 in stem
cell biology, cancer, and diabetes, very little is known of its
regulation [43,47]. Our initial efforts to use cells null for the VDR
were hindered by the unexpected inability of these cells to respond
to exogenous 1,25(OH)2D3/VDR by regulating endogenous
genes. As such, we used CaCo2 cells, a cell line that is well
characterized in the context of vitamin D research. These cells
increase TCF7L2 mRNA and TCF-4 protein in response to
1,25(OH)2D3, an effect that is dependent upon the VDR and
density. Since VDR is a transcription factor, we searched for
putative VDREs within the promoters of both the human and
mouse gene and although we identified numerous binding
elements, none were important in the regulation of TCF7L2 by
VDR/1,25(OH)2D3. Inhibition of protein synthesis abolishes
1,25(OH)2D3-mediated induction of TCF7L2 mRNA, indicating
that protein synthesis is required for this effect. Although this
implies that the VDR/1,25(OH)2D3 is directly regulating a
modulator of TCF7L2 expression, we cannot completely preclude
a direct mechanism of activation, given that the VDR may still be
binding to unidentified VDREs within the TCF7L2 promoter
region or even in enhancer elements far upstream or within
intronic sequences [37,48–50]. Although the induction of
CYP24A1 mRNA is also limited by the inhibition of protein
synthesis, it likely requires continued synthesis of co-activators to
achieve the sheer magnitude of response to ligand. Furthermore,
treatment with 1,25(OH)2D3 resulted in a 20–100 fold induction of
CYP24A1 at CHX concentrations that completely block TCF7L2
induction. Thus, in combination with the reporter data, and the
ChIP data, we believe that the mechanism of regulation is very
likely to be indirect. Given the modest increase in TCF7L2 mRNA
and the rather more robust increase in TCF-4 protein, we consider
that a micro RNA (miRNA) phenomenon may be contributing, in
tandem with mRNA induction via a 1,25(OH)2D3-sensitive
intermediary, to the increase in TCF-4 protein. Indeed,
1,25(OH)2D3 has recently been shown to regulate the expression
of some miRNAs [51].
The impact of increased TCF-4 was of particular interest in the
context of CaCo2 cells, since they harbor a somatic APC mutation
that allows abundant, activated b-catenin to accumulate in the
nucleus. Treatment of CaCo-2 cells for 24 hours with ligand
caused a modest but consistent increase in TopFlash activity which
is likely due to the increase in TCF-4 protein. We propose a model
whereby in the context of normal cells, or in cancers that do not
have abundant activated b-catenin, an up-regulation of TCF-4
would enhance repression of TCF/b-catenin responsive genes in
conjunction with the other 1,25(OH)2D3-mediated b-catenin
crosstalk previously mentioned. Although b-catenin is typically
associated with a cancer promoting phenotype, there are some
instances where b-catenin has anti-cancer properties. Sulindac and
butyrate, both of which are ascribed anti-cancer properties in the
colon [52,53] also stimulate b-catenin activity. Butyrate facilitates
induction of apoptosis in a number of colon carcinoma cell lines,
an effect that is thought to be partially mediated by b-catenin
activity [54]. Interestingly, CaCo2 cells were one of the only cell
lines that did not respond to butyrate by up-regulating TCF/b-
catenin activity, however, these cells, unlike the others assayed, do
not undergo apoptosis following butyrate treatment; rather they
undergo differentiation [54]. CaCo2 cells do, however, undergo
apoptosis in response to treatment with vitamin D agonists [55].
Thus, the short-lived up-regulation of TCF-4 by 1,25(OH)2D3 in
CaCo2 cells that we report, here, may facilitate 1,25(OH)2D3-
induced apoptosis in cells with abundant b-catenin, that is
Figure 7. CaCo2 cells up-regulate TopFlash activity in response
to 24-hour treatment with 1,25(OH)2D3. CaCo2 cells were
transfected for 24 hours with TopFlash, Renilla and different amounts
of VDR and treated for a subsequent 24 hours with 10
27 M 1,25(OH)2D3
or EtOH. Luciferase data were normalized to Renilla and FopFlash and
plotted relative to each EtOH-treated control sample. Error bars
represent SEM. p-values reported are from student’s t-test. RLU: Relative
Light Units.
doi:10.1371/journal.pone.0007872.g007
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follow up to the butyrate-induced activation of TCF/b-catenin
activity showed that butyrate, also induced initiation of c-myc
transcription in SW837 cells, presumably as a direct result of
increased TCF/b-catenin activity. The elongation of this tran-
script, however, was halted by treatment with butyrate, such that
overall c-myc transcripts were reduced [56]. These data indicate
that b-catenin activity may be required for some anti-cancer
effects, and that the pro-cancer effects may be mitigated by a
simultaneous transcription-blockage mechanism. Furthermore, in
colorectal cancer cells that have overactive b-catenin, TCF-4 is
known to be growth inhibitory, as RNAi-mediated disruption of its
expression facilitates b-catenin activity and cell growth in both
DLD-1 cells (APC mutation) and HCT116 cells (activating b-
catenin mutation) [57]. Recent data also show TCF-4 is lost in
human breast cancers and abundant in the surrounding normal
tissue, indicating that TCF-4 is a tumor suppressor in this tissue
[58]. These data further support the idea that VDR and
1,25(OH)2D3-mediated up-regulation of TCF-4 has an anti-cancer
role in the colon and mammary gland.
It is of particular interest to determine the downstream mediator
of 1,25(OH)2D3-induced up-regulation of TCF-4. Understanding
the regulation of TCF7L2 may have implications other than in the
context of cancer research. For example the TCF7L2 locus shows
remarkable linkage disequilibrium with type-2 diabetes (Reviewed
in [59]). It is currently not understood what the risk alleles convey
about the TCF-4 protein, and an obvious role for the protein in
this disease is not clearly defined. 1,25(OH)2D3 has also been
implicated in a protective role against type 1 and type 2 diabetes
[60–62], and the regulation of TCF-4 we show here may play a
role in disease establishment, progression, and treatment.
Furthermore, lack of TCF-4 has been associated with Ileal
Crohn’s disease, due to downstream regulation of proteins
involved in the response to bacteria [63]. Crohn’s is not only a
debilitating disease, but it is also believed to be a precursor to GI
cancer (Reviewed in [64]). The discovery of additional regulators
of TCF-4 expression may well lead to a better understanding of
the etiology of these diseases as well as potential therapeutic targets
in their treatment.
Materials and Methods
Cell Lines and Plasmids
VDR145
+/+ and VDRK240
2/2 cells were a kind gift from Dr.
JoEllen Welsh. They are maintained in DMEM-F12 (1:1)
(Invitrogen Cat. #11330-032) supplemented with 5% fetal bovine
serum. CaCo2 cells were obtained by the ATCC and maintained
in DMEM (Invitrogen 11995-065) supplemented with 5% fetal
bovine serum. VP16 b-catenin was generated as described [2].
Wild-type VDR and VDRE-luc plasmids were a kind gift from
Dino Moras [65]. The CMV-p53 construct was a kind gift from
Dr. Maria Laura Avantaggiati. The TCF7L2 plasmid as well as
the TopFlash and FopFlash were a kind gift from Marc van de
Wetering [66]. pcDNA3.1 is available from Invitrogen (cat.
#V79020). For cloning of the TCF7L2 reporter constructs,
genomic DNA was harvested from VDR145
+/+ cells and used to
amplify the mouse TCF7L2 promoter with the following primers: -
2068-luc: 59-GGA CTG TGA TTC TCA CCC G-39 (forward),
and 59-CCC CAA AAA AAT ACT GCA AGA A-39 (reverse)
using Invitrogen’s Platinum Taq PCR amplification kit (Cat
#10966-018) and TA cloned into pCR8/GW/TOPO vector (Cat
#K250020SC). Recombination with a Gateway-compliant pGL3
expression vector, a kind gift from Dr. Caroline Hurley’s
laboratory [67], was performed with LR-Clonase (Invitrogen
Cat #11791-019). Candidate clones were sequenced with RV3
(59-CTA GCA AAA TAG GCT GTC C-39) and GLprimer2 (59-
CTT TAT GTT TTT GGC GTC TTC C-39) primers. The
21037 construct was generated with the following primers: (XhoI
site added) 59-CTC GAG GAG AGG TAA GCC TTC TTT
TGG AC-39 (forward); (HindIII site added) 59-AAG CTT CAG
CAG CAA TTT TGG AAG AAA AAT GA-39 (reverse). Both
amplicon and pGL3-Luc-Promoter (Promega Cat. #E1761) was
digested with HindIII and XhoI (digestion with these two enzymes
removes the SV40 promoter, making this plasmid analogous to




2/2 cells were seeded to ,70%
confluency and transfected with the indicated amounts of VDR,
pcDNA3.1, or siRNA against VDR (Dharmacon Cat #LQ-
003448-00) or a non-targeting siRNA (Dharmacon Cat #D-
001810-10) using Lipofectamine 2000 (Invitrogen, Cat.
#11668019) according to the manufacturer’s recommendations.
Cells were harvested in ice-cold RIPA buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1% NP-40, .5% sodium deoxycholate,
1 mM EDTA, .1% SDS,) supplemented with protease inhibitor
cocktail (Roche Cat #11836153001, plus 1 mM sodium vanadate,
and 50 mM sodium fluoride) with shaking for 15 minutes. After
cell scraping lysates were drawn three times through an 18 Gauge
needle and the insoluble fraction was removed by centrifugation at
21,000 g for 10 minutes at 4uC. Proteins were quantified via
Bradford Assay (BioRad Cat. #s 500-0113, 500-0114, 500-0115).
10 mg of protein were separated on 4–12% Bis-Tris gels
(Invitrogen Cat. #NP0336) with MES buffer (Invitrogen Cat.
#NP0002) and transferred to Protran nitrocellulose (Whatman
#10401396). Blots were blocked for at least an hour in 5% non-fat
milk solution made up in PBS plus .1% Tween 20 (PBST), and
then incubated overnight at 4uC with 1:500 dilution of the
following antibodies: TCF-4 (Cell Signaling Cat #2566, Cell
Signaling Cat #2569, Upstate Cat #05-511), LEF-1 (Cell
Sigalning Cat #2230), TCF-3 (Cell Signaling Cat #2883),
TCF-1 (Cell Signaling Cat #2203VDR (Santa Cruz Cat. #sc-
13133, BioMeda V4045). GAPDH control blots were incubated in
1:10,000 dilution (Fitzgerald Cat. #10R-G109A) for 1 hour at
room temperature. Blots were washed at least three times for 5
minutes each in PBST, followed by incubation with affinity-
purified, peroxidase-labeled IgG secondary antibody (goat-anti-
rabbit: KPL, Cat. #074-1506; goat-anti-mouse: KPL, Cat. #074-
1806) diluted in 5% non-fat milk in PBST. Blots were exposed via
chemiluminescence (GE Healthcare #RPN2106, Millipore Im-
mobilon Cat #WBKLS0050).
GST Pulldown
GST fusion proteins were generated and attached to GST beads
as described [3]. 500 mg of protein from whole cell lysates of
VDR145
+/+ and VDRK240
2/2 cells (harvested as described in
Western Blot) were incubated with 20 uL of bead-bound GST-b-
catenin, GST-dTCF-b-Cat, or beads alone for 4 hours at 4uC.
Beads were collected by 1-minute centrifugation at 3000 rpm.
Beads were washed three times with 500 mL of cold RIPA buffer.
Proteins were eluted in 30 mL of sample buffer by heating at 92uC
for 3 minutes. Proteins were separated on a polyacrylamide gel





cells were seeded in 12-well plates. 150 ng of reporter, 40 ng of
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transfected into the cells via Lipofectamine PLUS (Invitrogen Cat.
#10964-013) according to the manufacturer’s protocol. 48 hours
after transfection, proteins were collected with 300 mL Passive
Lysis Buffer.
All other luciferase assays. CaCo2 and VDRK240
2/2
cells were seeded in a 24-well plate to 70% confluency and allowed
to adhere overnight. Cells were transfected using Lipofectamine
2000 at the recommended dilution. Cells were transfected with a
total of .8 mg of DNA per well (CaCo2: .2 mg Reporter, .02 mg
TK-Renilla,. 6mg VDR, pcDNA3.1, or ratio combination of both,
or p53; VDRK240
2/2:. 4mg Reporter, .04 mg TK-Renilla,. 4mg
VDR, pcDNA3.1 or ratio combination of both, or p53). For
experiments with mutated -2068-luc, ‘‘low’’ VDR is .2 mg and
‘‘high’’ VDR is .4 mg. Lipid complexes were removed after four
hours and replaced with complete media. Cells were treated
24 hours after transfection with 10
27 M 1,25(OH)2D3 (Sigma Cat.
#D1530) or an equal volume of ethanol (EtOH), the vehicle
control in DMEM:F12 plus 5% charcoal stripped fetal calf serum.
Lysates were harvested by incubating with 70 mL Passive Lysis
Buffer at room temperature for 15 minutes. Lysates were analyzed
LARII and Stop & Glo. All reagents are components of the Dual
Luciferase Kit (Promega Cat. #E1960). Results were normalized
for transfection efficiency by dividing Luciferase readout by Renilla
readout. Background reporter activity was accounted for by
subtracting FopFlash from and empty-vector control from
TCF7L2 reporter readouts. Data was plotted with GraphPad,
Prism, and subjected to two-way ANOVA or t-tests to test for
significant differences among samples.
Quantitative PCR
CaCo2 and VDRK240
2/2 cells were seeded in six-well plates
to a confluency of 70–80%.
Exogenous VDR experiment. Cells were transfected with a
total of 4 ug of DNA (VDR, pcDNA3.1 or a mixture thereof).
24 hours after transfection, cells were treated for an additional
24 hours with 10
27 M 1,25(OH)2D3. Total RNA was harvested
using .5 mL of Trizol reagent (Invitrogen Cat #15596-018)
followed by shaking with 100 mL of chloroform and 20 minutes at
21,0006g and 4uC. RNA was precipitated by adding an equal
volume (300 mL) of 100% EtOH to the aqueous phase. RNA was
captured, cleaned and eluted using RNeasy Kit (Qiagen Cat
#74106). Total RNA was diluted to uniform concentration. RNA
was subjected to reverse transcription PCR with Applied
Biosystems TaqMan Reverse Transcription Reagents Kit (Cat
#N8080234). Subsequent cDNA was used in a quantitative
amplification reaction using Applied Biosystems TaqMan
Universal Master Mix (Cat #4304437) with the following
primer/probes: human CYP24A1 (Hs00167999_m1), human
TCF7L2 (Hs01009053_m1), human GAPDH (Hs99999905_m1),
mouse TCF7L2 (Mm01261075_m1), mouse b-actin
(Mm01205647_g1). Data were normalized to the housekeeping
gene (GAPDH or b-actin) and fold change was plotted as an
average of at least three biological replicates.
Time course experiment. Cells were seeded and allowed to
adhere for 24 hours. Complete media was replaced with media
containing 5% charcoal-stripped FCS. Cells were treated 48-, 24-,
8-, 4-, and 2-hours before simultaneous harvest and RNA was
collected and processed for qPCR as described above.
Cycloheximide experiments. CaCo2 cells were seeded at
70% confluency. CHX was dissolved in 100% EtOH at a final
stock concentration of 25 mg/mL immediately before use.
DMEM supplemented with 5% charcoal-stripped fetal calf
serum was spiked with CHX (or an equal volume of 100%
EtOH) to a final concentration of 200 mg/mL. From this, serial
dilutions were made down to 12.5 mg/mL. Cells were pre-treated
for 30 minutes with different concentrations of CHX and then
with 10
27 M 1,25(OH)2D3 or EtOH was added to the CHX-
containing media for 24 hours. RNA was harvested and subjected
to qPCR as described but also using DKK-4 qPCR primers
(Applied Biosystems Cat # Hs00205290_m1).
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using Stratagene’s
QuikChange II kit (Cat #200523-5). Primers were designed to
mutate the two central nucleotides of each hexamer (bold) to two
thymidine residues (underlined). The reverse compliment of each
primer was also used in the PCR-based reaction. The sequences of






CaCo2 cells were seeded to 80% confluency in 15 cm dishes
and allowed to adhere overnight. Cells were treated for four hours
with 10
27 M 1,25(OH)2D3. Proteins and nucleic acids were
crosslinked by adding formaldehyde to a final concentration of 1%
and incubated for 15 minutes at 37uC. Crosslinking was stopped
by adding .125 M glycine (in PBS with protease inhibitor tabs,
Roche Cat #04693116001) for five minutes. Cells were washed
twice with cold PBS plus protease inhibitor tabs, and scraped into
2 mL PBS. Cells were pelleted and re-suspended in 200 mLo f
SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl
pH 8.1). Cells were sonicated thrice at 15 seconds pulse-45
seconds ice at power level three on a Microson Ultrasonic Cell
Disruptor (Model XL2007). Volumes were brought up to 2 mL by
adding 1.8 mL of ChIP Dilution Buffer (.01% SDS, 1.1% Triton
X 100, 1.2 mM EDTA, 167 mM NaCl, 16.7 Tris-HCl, pH 8.1)
plus protease inhibitors. Protein concentration was assayed via
Bradford Assay as described in the Western Blot section. 300 mgo f
protein was pre-cleared for 2 hours at 4uC with rotation using
50 mL salmon sperm DNA/BSA/protein A agarose beads
(Millipore Cat #16–157) plus rabbit pre-immune serum (Thermo
Scientific Cat #31884). Beads were removed by centrifugation for
5 minutes at 5006g. Input controls were collected at this time.
1 mg of the following antibodies was added to each pre-cleared
sample and rotated overnight at 4uC: rabbit-anti-VDR (Santa
Cruz Cat. #sc-1008), rabbit IgG (control) (Santa Cruz Cat. #sc-
2027), rabbit-anti-RXR (Santa Cruz Cat #sc-553). Antibodies
were pulled down by the addition of 50 mL protein A beads and
rotation for 2 hours at 4uC. Bead/antibody/protein/DNA
complexes were pelleted at 5006g for 2 minutes and washed by
five-minute rotation with 1 mL of the following wash buffers: once
with low salt buffer (.1% SDS, 1% Triton X 100, 2 mM EDTA,
20 mM Tris-HCl pH 8.1, 150 mM NaCl); once with high salt
buffer (1% SDS, 1% Triton X 100, 2 mM EDTA, 20 mM Tris-
HCl pH 8.1, 500 mM NaCl); once with LiCl buffer (.25 M LiCl,
1% NP40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl
pH 8.1), twice with TE buffer (10 mM Tris-HCl pH 8.1, 1 mM
EDTA). Proteins were eluted with 2615 minute rotations in
100 mL of 1% SDS, 0.1 M NaHCO3. Crosslinking was reversed
by incubation of eluates with NaCl (final concentration .2 M) at
65uC overnight. Proteins were subsequently digested by addition
of proteinase K (final concentration is 40 mg/mL) (Amresco Cat.
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Qiagen PCR Purification Module (Cat #28106). Eluates were
used as templates in the amplification of regions of the human
CYP24A1 and TCF7L2 promoters containing the putative
VDREs with primers as listed:
hTCF7L2 VDRE +88F, 59-GGA GGA GCT GTT TTG ATT
CG-39
hTCF7L2 VDRE +88R, 59-AAG ACC CCC AAG CAG AAA
AA-39
hTCF7L2 VDRE 2162F, 59-TTT TTC TGC TTG GGG
GTC TT-39
hTCF7L2 VDRE 2162R, 59-TCC TTG GGA ACG AGA
GAA AA-39
hTCF7L2 VDRE 2685F, 59-GGG GCG GCT AAC AAT
GAT-39
hTCF7L2 VDRE 2685R, 59-ATT GTC TTT CTG AAA
CCG CC -39
hTCF7L2 VDRE 2808F, 59-GGC GGT TTC AGA AAG
ACA AT-39
hTCF7L2 VDRE 2808R, 59-CCC AAG TGG GCT TTC
CTT-39
hTCF7L2 VDRE 23656F, 59-GCG AGA CTC CGT CTC
AAA AA-39
hTCF7L2 VDRE 23656R, 59-CCT GGC TCA GGC TAA
AGT CA-39
hTCF7L2 VDRE 23827F, 59-CCA AAT GGC AGA GAT
TTG AA-39
hTCF7L2 VDRE 23827R, 59-TGC CTT CCT CCC AAA
ATA TG-39
hCYP24 ChIP F: 59-CGA AGC ACA CCC GGT GAA CT-39
hCYP24 ChIP R: 59-CCA ATG AGC ACG CAG AGG AG-39
Density Experiment
CaCo2 cells were seeded in 6-well plates at the following
concentrations: Low density: 200,000 cells/well (20% confluent);
Medium density: 500,000 cells/well (50% confluent); High
density: 1,000,000 cells/well (70% confluent). Cells were allowed
to adhere overnight and then treated for 24 hours with 10
27 M
1,25(OH)2D3. Total RNA was harvested and subjected to qPCR
as described.
Statistics
Student’s t-test was used to determine significant differences
between samples in the luciferase assays for OT (Figure 1C and
1D) and TopFlash activity (Figure 7) (between VDR145
+/+ and
VDRK240
2/2 cells); mRNA for TCF7L2 of treated CaCo2 and
VDRK240
2/2 cells (Figure 3A and Supplementary Figure S1B)
(between EtOH- and 1,25(OH)2D3-treated samples); the time-
course of 1,25(OH)2D3 treatment of CaCo2 cells (Figure 3B)
(between 0-hour time-point and each individual time-point
thereafter); density experiments (Supplementary Figure S3)
(between EtOH- and 1,25(OH)2D3-treated samples); Cyclohexi-
mide experiments (Figure 6) (between EtOH- and 1,25(OH)2D3-
treated samples). One-tailed t-tests were used to analyze protein
densitometry of CaCo2 cells treated with 1,25(OH)2D3 (Figure 2E).
Two-way ANOVA was used to analyze luciferase data from
luciferase assays for -1037-luc plasmid (Figure 4C, left panel)
(between EtOH- and 1,25(OH)2D3-treated samples); -2068-luc
plasmid (Figure 4C, right panel and Supplementary Figure S4A),
and is mutated progeny (Figure 5B and Supplementary Figure
S4B) for a trend in expression with increasing VDR.
Supporting Information
Figure S1 VDRK240
2/2 cells are unable to increase TCF-4
protein or TCF7L2 mRNA expression in response to VDR and
1,25(OH)2D3. (A) Western blot for VDRK240
2/2 cells transfected
for different amounts of time with different amounts of VDR, as
indicated in the presence of full-serum (5% FBS). (B) VDRK240
2/
2 cells were transfected for 24 hours with different amounts of
VDR and treated for a subsequent 24 hours with 10
27 M
1,25(OH)2D3 or EtOH, as indicated. TCF7L2 mRNA was
assayed by qPCR. Error bars represent SEM. No statistically
significant differences were detected.
Found at: doi:10.1371/journal.pone.0007872.s001 (0.73 MB TIF)
Figure S2 Several colorectal cancer cell lines increase TCF-4
protein in response to 1,25(OH)2D3. Densitometry of three
replicates of western blots as performed as in Figure 2C. Data
were plotted relative to each cell-line EtOH-control. Upper and
lower TCF-4 bands were measured and plotted independently.
Error bars represent SEM.
Found at: doi:10.1371/journal.pone.0007872.s002 (0.58 MB TIF)
Figure S3 Density plays a role in the regulation of TCF-4 and
CYP24A1 in CaCo2 cells. CaCo2 cells were seeded at three
densities: Low (20%-), medium (50%-) and high (70%-confluency)
and treated for 24 hours with 10
27 M 1,25(OH)2D3. mRNAs
were analyzed by qPCR and plotted relative to the low-density
EtOH treated sample. Error bars represent SEM. Statistics
represent student’s t-test: *: p,.05.
Found at: doi:10.1371/journal.pone.0007872.s003 (0.52 MB TIF)
Figure S4 VDRK240
2/2 cells are able to regulate TCF7L2
reporter constructs in response to VDR and 1,25(OH)2D3. (A)
VDRK240
2/2 cells were transfected with -2068-luc, Renilla and
different amounts of VDR for 24 hours and treated for a
subsequent 24 hours with 10
27 M 1,25(OH)2D3 or EtOH, as
indicated. Luciferase proteins were analyzed and data were plotted
relative to 0 mg VDR/EtOH sample. Error bars represent SEM.
Statistics are generated with two-way ANOVA: ***: p,.0001. (B) -
2068-luc construct containing all three sets of half-site mutations
(d1502/d1153/d177) was transfected into VDRK240
2/2 cells
and treated with ligand as described in Figure 4C with only 3
concentrations of VDR (low, medium and high). Error bars
represent SEM. Statistics represent analysis using two-way
ANOVA: *p,.05. RLU-Relative Light Units.
Found at: doi:10.1371/journal.pone.0007872.s004 (0.63 MB TIF)
Figure S5 CYP24A1 induction by 1,25(OH)2D3 is reduced but
never abolished in response to cycloheximide treatment. CaCo2
cells were pre-treated for 30 minutes with different concentrations
of the protein synthesis inhibitor, Cycloheximide (CHX) before
addition of 10
27 M 1,25(OH)2D3 or EtOH for 24 hours, as
indicated. Analysis of mRNA abundance of CYP24A1 was assayed
by qPCR.
Found at: doi:10.1371/journal.pone.0007872.s005 (0.54 MB TIF)
Figure S6 No other members of the TCF/LEF family are up-
regulated in response to 1,25(OH)2D3 in CaCo2 cells. CaCo2 cells
were treated with 10
27 M 1,25(OH)2D3 (right lane) or EtOH (left
lane) for 24 hours. Whole cell lysates were blotted for LEF-1,
TCF-3 and TCF-1. GAPDH was assayed to demonstrate even
loading of lanes. Densitometry was measured and plotted relative
to the EtOH-control band.
Found at: doi:10.1371/journal.pone.0007872.s006 (1.00 MB TIF)
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